Listen to the article
Something has changed if you stroll through any upscale pharmacy in Dubai on a weekday afternoon. The diabetes and metabolic health section’s shelves move more quickly than they did in the past. Customers and pharmacists have longer, more technical conversations. Drug names that most people in the area couldn’t pronounce even two years ago are becoming more and more familiar. Ozempic. GLP-1. Tirzepatide. In the UAE, the vocabulary of a quiet medical shift has permeated daily life and is progressing more quickly than the healthcare system had anticipated.
The announcement made by Abu Dhabi in June 2025 may be the best example of this change. The Personalized Weight Management Programme, a structured, government-backed initiative that combines digital monitoring with actual clinical support and, perhaps most importantly, a reimbursement model for obesity medications, was introduced by the Department of Health in collaboration with the Abu Dhabi Public Health Centre.
Key Facts: Dubai & UAE Weight-Loss Healthcare Revolution
| Category | Details |
|---|---|
| Programme Name | Personalized Weight Management Programme — Abu Dhabi, June 2025 |
| Launched By | Department of Health – Abu Dhabi (DoH) & Abu Dhabi Public Health Centre (ADPHC) |
| Eligibility | Thiqa members aged 18 and above, clinically identified as overweight or obese |
| Key Components | Digital monitoring, personalized clinical support, innovative reimbursement model |
| Obesity Impact (UAE) | Can reduce life expectancy by up to 15 years; linked to diabetes, heart disease, and certain cancers |
| Key GLP-1 Drugs | Ozempic and similar GLP-1 therapies now reshaping food and pharmacy habits in the UAE |
| Surgical Option | Bariatric surgery — sustainable weight loss of 40–60 kg; only known cure for diabetes and hypertension |
| Non-Surgical Option | Intragastric balloon — 10-minute endoscopic procedure; guaranteed loss of 10–15 kg |
| Industry Partner | Eli Lilly (META region) — supporting reimbursement policy and clinical collaboration |
| Regional Significance | First-of-its-kind structured obesity programme in the GCC; sets precedent for reimbursement of obesity medications |
This is a significant change for an area where treating obesity has traditionally been viewed as a matter of personal discipline rather than medical policy. The program is available to Thiqa members who are 18 years of age or older and have been clinically diagnosed as overweight or obese. It provides thousands of individuals with a previously unavailable structured pathway into care.
The director-general of the Abu Dhabi Public Health Center, Dr. Rashid Obaid Al Suwaidi, admitted what doctors in the United Arab Emirates had long known in silence: there were no referral pathways. Physicians were able to diagnose obesity, give patients advice, and send them home with recommendations that many people couldn’t actually follow. Between clinical identification and ongoing support, there was no organized link. That bridge is currently being constructed, and the timing is crucial because obesity is a serious issue in the United Arab Emirates. It can shorten life expectancy by up to 15 years, and it exacerbates a number of other illnesses that are already taxing public health resources throughout the Gulf, including diabetes, hypertension, and heart disease.
Beyond government initiatives, Dubai’s weight-loss revolution is subtly changing healthcare. The class of injectable medications known as GLP-1 therapies, which includes Ozempic and related substances, is actually altering how people shop and eat in the United Arab Emirates. According to a Khaleej Times article, more people are shifting away from highly processed foods—not necessarily out of self-control, but rather because these drugs’ ability to suppress appetite makes it easier to make other decisions. Nutritionists and public health researchers are still working to fully comprehend this pharmacologically driven behavioral shift. Long-term sustainability is still a genuine and unanswered question.
Walking through some of Dubai’s more recent wellness clinics, the ones with digital check-in systems and spotless white interiors close to JLT and Downtown, gives the impression that the market has already made its wager. AI-guided exercise regimens, gut health diagnostics, smart gyms—the GCC wellness economy is vast and expanding swiftly.
However, the clinical aspect is catching up in ways that seem more resilient. For example, bariatric surgery has been practiced in the area for many years, but the discourse surrounding it has changed significantly. For many years, doctors at hospitals such as Dubai London Hospital have positioned it not just as a weight-loss procedure but as the best known treatment for type 2 diabetes and hypertension, resulting in sustainable weight loss of 40 to 60 kg in a matter of months with long-lasting effects. Patients who may have previously written off surgery as a last resort are now responding favorably to that framing.
Beyond its current offerings, Abu Dhabi’s new show is worth watching. It conveys the UAE’s view of obesity as a chronic illness that requires the same organized medical care as diabetes or heart disease, rather than as a lifestyle flaw. Eli Lilly’s Tony Terzis called the reimbursement policy a “paradigm shift,” and it’s difficult to disagree. When a government begins funding obesity treatment, it is sending a message about responsibility and compassion that permeates society. How soon other emirates will follow is still unknown. However, the precedent has been established, and that is more significant than it may appear in a region that moves quickly when it chooses to move.
